Literature DB >> 20944103

Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma.

Stéphanie Cludts1, Christine Decaestecker, Bryon Johnson, Jérôme Lechien, Xavier Leroy, Nadège Kindt, Herbert Kaltner, Sabine André, Hans-Joachim Gabius, Sven Saussez.   

Abstract

BACKGROUND/AIM: To examine the presence of macrophage migration inhibitory factor (MIF) quantitatively in relation to neoplastic progression of hypopharyngeal squamous cell carcinoma (HSCC).
MATERIALS AND METHODS: The presence of MIF was analysed by quantitative immunohistochemistry in sections of 81 HSCCs, and compared to 15 specimens of tumour-free epithelia (TF_E), 29 low-grade dysplasias (Low_D) and 25 high-grade dysplasias (High_D). In parallel, MIF expression was studied using Western blotting on a series of 19 fresh biopsies.
RESULTS: A significant increase in MIF staining intensity (mean optical density) was observed in carcinoma samples compared to TF_E (p<10(-6)), Low_D (p=0.0006) or High_D (p=0.0006). Immunohistochemical MIF positivity was significantly higher in HSCCs than in TF_E (p=0.00001) or Low_D (p=0.001). The percentage of MIF-immunopositive cells (labelling index) significantly decreased in parallel with an apparent loss of histological differentiation (p=0.003).
CONCLUSION: This study identified the presence of MIF as a parameter that positively correlates with neoplastic progression of HSCC and cell differentiation status.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20944103

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets.

Authors:  Nadège Kindt; Fabrice Journe; Guy Laurent; Sven Saussez
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

2.  Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies.

Authors:  Nadège Kindt; Julie Preillon; Herbert Kaltner; Hans-Joachim Gabius; Dominique Chevalier; Alexandra Rodriguez; Bryon D Johnson; Véronique Megalizzi; Christine Decaestecker; Guy Laurent; Sven Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-25       Impact factor: 4.553

3.  Involvement of CD74 in head and neck squamous cell carcinomas.

Authors:  Nadège Kindt; Jérôme R Lechien; Denis Nonclercq; Guy Laurent; Sven Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-25       Impact factor: 4.553

4.  Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.

Authors:  Ramona Schulz; Natalia D Marchenko; Lena Holembowski; Günter Fingerle-Rowson; Marina Pesic; Lars Zender; Matthias Dobbelstein; Ute M Moll
Journal:  J Exp Med       Date:  2012-01-23       Impact factor: 14.307

5.  HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.

Authors:  R Schulz; F Streller; A H Scheel; J Rüschoff; M-C Reinert; M Dobbelstein; N D Marchenko; U M Moll
Journal:  Cell Death Dis       Date:  2014-01-02       Impact factor: 8.469

Review 6.  Macrophage migration inhibitory factor: a potential driver and biomarker for head and neck squamous cell carcinoma.

Authors:  Sha-Sha Wang; Xiao Cen; Xin-Hua Liang; Ya-Ling Tang
Journal:  Oncotarget       Date:  2017-02-07

7.  Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer.

Authors:  Vincent Richard; Nadège Kindt; Christine Decaestecker; Hans-Joachim Gabius; Guy Laurent; Jean-Christophe Noël; Sven Saussez
Journal:  Oncol Rep       Date:  2014-06-16       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.